The Telomerase Reverse Transcriptase pipeline drugs market research report outlays comprehensive information on the Telomerase Reverse Transcriptase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Telomerase Reverse Transcriptase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Cardiovascular, and Central Nervous System which include the indications Unspecified Cancer, Glioblastoma Multiforme (GBM), Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Unspecified Cardiovascular Disorders, Critical Limb Ischemia, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis. It also reviews key players involved in Telomerase Reverse Transcriptase targeted therapeutics development with respective active and dormant or discontinued products.
The Telomerase Reverse Transcriptase pipeline targets constitutes close to 44 molecules. Out of which, approximately 38 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, and Discovery stages are 1, 1, 7, 5, 1, 18, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 2 molecule.
Telomerase Reverse Transcriptase overview
Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis.
For a complete picture of Telomerase Reverse Transcriptase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
